We are delighted to announce the new 2018 Consensus Statement for Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of theΒ International Ketogenic Diet Study Group.Β 

Matthew’s Friends are proud to be a part of this important update to the Consensus Statement, a key resource in the management of children with epilepsy and Ketogenic Dietary Therapies.

Congratulations to Professor Kossoff and all of the collaborators in producing this important and concise resource.

Click here to view the 2018 Consensus Statement

Ketogenic dietary therapies (KDTs) are established, effective non-pharmacologicΒ treatments for intractable childhood epilepsy.

For many years KDTs were implemented differently throughout the world due to lack of consistent protocols.Β In 2009,Β an expert consensus guideline for the management of children on KDT was published,Β focusing on topics of patient selection, pre-KDT counseling and evaluation, diet choiceΒ and attributes, implementation, supplementation, follow-up, side events, and KDT discontinuation. It has been helpful in outlining a state-of-the-art protocol, standardizingΒ KDT for multicenter clinical trials, and identifying areas of controversy and uncertainty for future research.

Now one decade later, the organizers and authors of thisΒ guideline present a revised version with additional authors, in order to include recentΒ research, especially regarding other dietary treatments, clarifying indications for use,Β side effects during initiation and ongoing use, value of supplements, and methods ofΒ KDT discontinuation. In addition, authors completed a survey of their institution’sΒ practices, which was compared to responses from the original consensus survey, toΒ show trends in management over the last 10 years.

Eric H. Kossoff is a professor of neurology and pediatrics at Johns Hopkins Hospital in Baltimore